Department of Radiation Oncology, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Ismaninger Str. 22, 81675, München, Germany.
Institute of Innovative Radiotherapy (iRT), Helmholtz Zentrum München, Oberschleißheim, Germany.
Radiat Oncol. 2019 Jun 18;14(1):109. doi: 10.1186/s13014-019-1293-1.
The aim of this study was to compare dose-volume histogram (DVH) with dose-mass histogram (DMH) parameters for treatment of left-sided breast cancer in deep inspiration breath-hold (DIBH) and free breathing (FB). Additionally, lung expansion and anatomical factors were analyzed and correlated to dose differences.
For 31 patients 3D conformal radiation therapy plans were retrospectively calculated on FB and DIBH CTs in the treatment planning system. The calculated doses, structures and CT data were transferred into MATLAB and DVHs and DMHs were calculated. Mean doses (Dmean), volumes and masses receiving certain doses (Vx, Mx) were determined for the left lung and the heart. Additionally, expansion of the left lung was evaluated using deformable image registration. Differences in DVH and DMH dose parameters between FB and DIBH were statistically analyzed and correlated to lung expansion and anatomical factors.
DIBH reduced Dmean (DVH) and relative V20 (V20 [%]) of the left lung in all patients, on average by - 19 ± 9% (mean ± standard deviation) and - 24 ± 10%. Dmean (DMH) and M20 [%] were also significantly reduced (- 12 ± 11%, - 16 ± 13%), however 4 patients had higher DMH values in DIBH than in FB. Linear regression showed good correlations between DVH and DMH parameters, e.g. a dosimetric benefit smaller than 8.4% for Dmean (DVH) in DIBH indicated more irradiated lung mass in DIBH than in FB. The mean expansion of the left lung between FB and DIBH was 1.5 ± 2.4 mm (left), 16.0 ± 4.0 mm (anterior) and 12.2 ± 4.6 mm (caudal). No significant correlations were found between expansions and differences in Dmean for the left lung. The heart dose in DIBH was reduced in all patients by 53% (Dmean) and this dosimetric benefit correlated to lung expansion in anterior.
Treatment of left-sided breast cancer in DIBH reduced dose to the heart and in most cases the lung dose, relative irradiated lung volume and lung mass. A mass related dosimetric benefit in DIBH can be achieved as long as the volume related benefit is about ≥8-9%. The lung expansion (breathing pattern) showed no impact on lung dose, but on heart dose. A stronger chest breathing (anterior expansion) for DIBH seems to be more beneficial than abdominal breathing.
本研究旨在比较深吸气屏气(DIBH)和自由呼吸(FB)治疗左侧乳腺癌时剂量-体积直方图(DVH)和剂量-质量直方图(DMH)参数。此外,还分析了肺扩张和解剖因素,并将其与剂量差异相关联。
对 31 例患者的 FB 和 DIBH CT 在治疗计划系统中进行了回顾性 3D 适形放疗计划计算。将计算出的剂量、结构和 CT 数据传输到 MATLAB 中,并计算出 DVH 和 DMH。确定左肺和心脏的平均剂量(Dmean)、接受一定剂量的体积(Vx)和质量(Mx)。此外,还使用可变形图像配准评估左肺的扩张。统计分析 FB 和 DIBH 之间 DVH 和 DMH 剂量参数的差异,并与肺扩张和解剖因素相关联。
DIBH 使所有患者的左肺 Dmean(DVH)和相对 V20(V20 [%])平均降低-19±9%(均值±标准差)和-24±10%。Dmean(DMH)和 M20 [%]也显著降低(-12±11%,-16±13%),然而 4 例患者在 DIBH 中 DMH 值高于 FB。线性回归显示 DVH 和 DMH 参数之间存在良好的相关性,例如,DIBH 中 Dmean(DVH)的剂量获益小于 8.4%,表明 DIBH 中肺质量的照射剂量大于 FB。左肺在 FB 和 DIBH 之间的平均扩张为 1.5±2.4mm(左侧)、16.0±4.0mm(前)和 12.2±4.6mm(后)。左肺 Dmean 之间的扩张与差异之间未发现显著相关性。DIBH 中所有患者的心脏剂量均降低了 53%(Dmean),这种剂量获益与前向肺扩张相关。
DIBH 治疗左侧乳腺癌可降低心脏和大多数情况下肺剂量、相对受照肺体积和肺质量。只要体积相关获益约为≥8-9%,就可以实现基于质量的剂量获益。肺扩张(呼吸模式)对肺剂量没有影响,但对心脏剂量有影响。对于 DIBH,更强的胸部呼吸(前向扩张)似乎比腹部呼吸更有益。